文献速递流行病学与生物统计基础与转化研究

孟德尔随机化研究:血清尿酸水平对慢性肾病风险无因果效应

No causal effects of serum urate levels on the risk of chronic kidney disease: A Mendelian randomization study.
PubMed 文献 · PLoS Med · 2019-01-15

研究采用孟德尔随机化方法,利用欧洲血统人群的汇总全基因组关联数据、英国生物银行电子病历链接数据及人群队列,评估血清尿酸水平对慢性肾病和估算肾小球滤过率的因果影响。结果显示尿酸对eGFR和CKD风险均无因果效应(所有P>0.05),与观察到的流行病学关联形成对比。

要点

  • 孟德尔随机化分析未发现血清尿酸对eGFR或CKD风险有因果效应。
  • 观察性队列中尿酸升高与eGFR下降及CKD风险增加相关,但可能非因果。
  • 降低血清尿酸水平 unlikely 减少CKD发生风险。

核心结论

  • 基于遗传学的因果推断方法不支持血清尿酸水平对eGFR水平或CKD风险存在因果效应。

研究设计与样本

  • 采用孟德尔随机化方法,使用欧洲血统人群的汇总全基因组关联数据(尿酸N=110,347;痛风N=69,374;eGFR N=133,413;CKD N=117,165)、英国生物银行电子病历链接数据(N=335,212)及人群队列(N=13,425)。

主要发现

  • 所有孟德尔随机化分析均显示尿酸对eGFR水平和CKD风险无因果效应(所有P>0.05)。
  • 在4个人群队列中,尿酸每升高1 mg/dl(59.48 μmol/l),eGFR变化为-1.99 ml/min/1.73 m2(95% CI -2.86至-1.11;P=8.08×10^-6),CKD的OR为1.48(95% CI 1.32至1.65;P=1.52×10^-11)。
  • 孟德尔随机化方法显示尿酸对痛风风险有因果效应,每1 mg/dl升高的OR估计范围为3.41至6.04(所有P<10^-3),作为阳性对照。
  • 孟德尔随机化分析有>99%把握度检测到与观察性关联同等大小的尿酸对CKD风险的因果效应。

临床怎么用

  • 减少血清尿酸水平不太可能降低CKD发生风险。

局限性

  • 遗传扰动的终生效应可能与急性扰动不同。
  • 无法研究非欧洲人群。
  • 所用数据集之间存在部分样本重叠。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Studies have shown strong positive associations between serum urate (SU) levels and chronic kidney disease (CKD) risk; however, whether the relation is causal remains uncertain. We evaluate whether genetic data are consistent with a causal impact of SU level on the risk of CKD and estimated glomerular filtration rate (eGFR). METHODS AND FINDINGS: We used Mendelian randomization (MR) methods to evaluate the presence of a causal effect. We used aggregated genome-wide association data (N = 110,347 for SU, N = 69,374 for gout, N = 133,413 for eGFR, N = 117,165 for CKD), electronic-medical-record-linked UK Biobank data (N = 335,212), and population-based cohorts (N = 13,425), all in individuals of European ancestry, for SU levels and CKD. Our MR analysis showed that SU has a causal effect on neither eGFR level nor CKD risk across all MR analyses (all P > 0.05). These null associations contrasted with our epidemiological association findings from the 4 population-based cohorts (change in eGFR level per 1-mg/dl [59.48 μmol/l] increase in SU: -1.99 ml/min/1.73 m2; 95% CI -2.86 to -1.11; P = 8.08 × 10(-6); odds ratio [OR] for CKD: 1.48; 95% CI 1.32 to 1.65; P = 1.52 × 10(-11)). In contrast, the same MR approaches showed that SU has a causal effect on the risk of gout (OR estimates ranging from 3.41 to 6.04 per 1-mg/dl increase in SU, all P < 10-3), which served as a positive control of our approach. Overall, our MR analysis had >99% power to detect a causal effect of SU level on the risk of CKD of the same magnitude as the observed epidemiological association between SU and CKD. Limitations of this study include the lifelong effect of a genetic perturbation not being the same as an acute perturbation, the inability to study non-European populations, and some sample overlap between the datasets used in the study. CONCLUSIONS: Evidence from our series of causal inference approaches using genetics does not support a causal effect of SU level on eGFR level or CKD risk. Reducing SU levels is unlikely to reduce the risk of CKD development.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Jordan DM, Choi HK, Verbanck M, et al. No causal effects of serum urate levels on the risk of chronic kidney disease: A Mendelian randomization study. PLoS Med. 2019. PMID: 30645594. doi:10.1371/journal.pmed.1002725

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。